Status:

COMPLETED

Maxillary Expansion Treatment of Pediatric OSA

Lead Sponsor:

University of British Columbia

Conditions:

Obstructive Sleep Apnea

Eligibility:

All Genders

6-10 years

Phase:

NA

Brief Summary

Obstructive Sleep Apnea is a serious medical condition affecting an estimated 1-5% of children. The disease is believed to have several overlapping causes including large tonsils and small or narrow j...

Detailed Description

Background Literature Review Obstructive sleep apnea syndrome (OSAS) is a sleep disorder characterized by recurrent, partial or complete episodes of upper airway obstruction, commonly associated with ...

Eligibility Criteria

Inclusion

  • Ages 6.0 to 10.0 years at the time of screening;
  • Diagnosed with obstructive sleep apnea defined as AHI\>2, confirmed on overnight, laboratory-based PSG;
  • Parental report of witnessed apneas or habitual snoring (on average more than 3 nights per week);
  • Deemed to be a candidate for ME by orthodontic evaluation;
  • Deemed to be a candidate for tonsillectomy and adenoidectomy by otolaryngologic evaluation.

Exclusion

  • Severe OSA or significant hypoxemia in the presence of tonsillar or adenoid hypertrophy requiring surgical intervention defined as AHI\>25 or SpO2 \<90% for \>2% sleep time.
  • An associated craniofacial syndrome or anomaly, including cleft lip and/or palate, or any anatomic or systemic condition that would otherwise exclude the patient from orthodontic treatment.
  • Recurrent tonsillitis that meets American Academy of Otolaryngology - Head and Neck Surgery clinical practice guidelines for surgery.
  • Extremely overweight defined as a body mass index z-score \> 2.99 for age group and sex.
  • Severe health problems that could be exacerbated by delayed treatment for OSA, including: severe cardiopulmonary disorders (e.g., cystic fibrosis, congenital heart disease); sickle cell disease; poorly controlled asthma (with \> 1 hospitalization in last year); epilepsy requiring medication; diabetes (type 1 or type 2) requiring medication; doctor-diagnosed heart disease; or a history of stage II hypertension (HTN) defined as \> 99% percentile and/or requiring medication.
  • Psychiatric or behavioral disorders that would otherwise exclude the patient from receiving orthodontic treatment

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2018

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT01837914

Start Date

May 1 2013

End Date

December 1 2018

Last Update

November 22 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

BC Children's Hospital Otolaryngology Department

Vancouver, British Columbia, Canada, V6H 3N1